Exploring Thioredoxin-Interacting Protein (TXNIP) as a Therapeutic Target for Cardiovascular Diseases
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Thioredoxin-interacting protein (TXNIP) drives cardiovascular disease (CVD) by promoting oxidative stress and inflammation. Targeting TXNIP offers a promising therapeutic strategy for mitigating CVD progression and improving patient outcomes.
Area Of Science
- Biochemistry
- Molecular Biology
- Cardiology
Background
- Cardiovascular diseases (CVDs) are a leading global cause of mortality.
- Oxidative stress is a key factor in CVD pathogenesis.
- Thioredoxin-interacting protein (TXNIP) is a critical redox regulator implicated in CVD.
Purpose Of The Study
- To review the role of TXNIP in cardiovascular disease progression.
- To elucidate the molecular mechanisms by which TXNIP contributes to CVD.
- To explore TXNIP as a potential therapeutic target for CVD.
Main Methods
- Literature review of TXNIP's involvement in CVD.
- Analysis of TXNIP's regulatory functions in oxidative stress and inflammation.
- Examination of signaling pathways influenced by TXNIP in cardiovascular contexts.
Main Results
- TXNIP acts as a pro-oxidant, disrupting antioxidant function and causing redox imbalance.
- TXNIP activates the NLRP3 inflammasome, leading to IL-1β and IL-18 release and inflammation.
- TXNIP modulates apoptosis and pyroptosis by altering TRX/ASK1 interactions.
- TXNIP regulates key signaling pathways including TXNIP/SIRT1/FOXO1, TXNIP/Redd1, TLR4/NF-κB/TXNIP/NLRP3, and NRF2/TXNIP.
Conclusions
- TXNIP is a central mediator of oxidative stress and inflammation in CVD.
- TXNIP plays a significant role in vascular damage, endothelial dysfunction, and cell death pathways.
- Targeting TXNIP presents a potential therapeutic avenue for treating cardiovascular diseases.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor tyrosine kinases:
Receptor tyrosine kinases (RTKs) phosphorylate specific tyrosines on the signaling proteins. RTKs include various growth factor receptors,...
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...